Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS).
Mina M SwihaDuncan E K SutherlandGolmehr SistaniAlireza KhatamiRami M AbazidAmol MujoomdarDaniele P WisemanJonathan G RomsaRobert H ReidDavid T LaidleyPublished in: Journal of cancer research and clinical oncology (2021)
ClinicalTrials.gov identifier: NCT02236910, Retrospectively registered on September, 2014.